Acer Therapeutics Inc
ACER
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $17.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.77 |
| Beta | 0.44 |
| Outstanding Shares | 24,464,000 |
Return
| Return on Equity | 127.59% |
|---|---|
| Return on Assets | -435.08% |
| Return on Invested Capital | 29.07% |
Valuation & Multiples
| P/E Ratio | -0.4 |
|---|---|
| PEG | -0.2 |
| Price to Sales | - |
| Price to Book Ratio | -0.33 |
| Enterprise Value to Revenue | 47.22 |
| Enterprise Value to EBIT | -1.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -0.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Acer Therapeutics Inc
CEO: Christopher Schelling Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER...